ABSTRACT
The objective of this multinational open-label, prospective study was to collect, under naturalistic conditions, data on the effectiveness and tolerability of first-line monotherapy with valproate in subjects newly or recently diagnosed with focal onset epilepsy. Patients were treated with sustained release sodium valproate. Seizure control and occurrence of adverse events were assessed after 6 months. Around 1192 adults and 792 children were included. The mean daily valproate dose was 683 mg in children and 987 mg in adults. The retention rate at 6 months was 90.0%. At this time, 77% of subjects were seizure free (83.7% of children and 72.7% of adults). Adverse events possibly related to treatment were observed in 10.2% of subjects, leading to treatment modification for 1.7%. The most common adverse events were weight gain, gastro-intestinal, neurological and skin disorders. Sustained release sodium valproate is effective and shows acceptable tolerability as first-line monotherapy in focal onset epilepsy.
Subject(s)
Anticonvulsants/administration & dosage , Anticonvulsants/adverse effects , Epilepsies, Partial/drug therapy , Valproic Acid/administration & dosage , Valproic Acid/adverse effects , Adolescent , Adult , Age Factors , Brain Diseases/chemically induced , Child , Delayed-Action Preparations , Dose-Response Relationship, Drug , Epilepsy/drug therapy , Female , Gastrointestinal Diseases/chemically induced , Humans , International Cooperation , Male , Middle Aged , Prospective Studies , Skin Diseases/chemically induced , Treatment Outcome , Weight Gain/drug effectsABSTRACT
An atypical case of congenital myopathy characterised by a low frequency of hypoplastic type 2A fibres, type 2B fibre deficiency and type 1 fibre predominance is reported. Our patients are siblings, a 10 year old girl and a 7 year old boy. Both children suffered from ophthalmoplegia and muscle weakness, and the boy also showed signs of psychomotoric retardation. A muscle biopsy from musculus trapezius has shown type 1 fibre predominance and hypoplastic type 2 fibres.
